- Perelson AS, Ribeiro RM. Introduction to modeling viral infections and immunity. Immunol Rev. 2018; 285: 5-8.
- Canini L, Perelson AS. Viral kinetic modeling: state of the art. J PharmacokinetPharmacodyn. 2014;41:431-43.
- Hirano N, Fujiwara K, Matumoto M. Mouse hepatitis virus (MHV-2) Jap J Microbiol. 1976;20: 219–25.
- Schneider M, Ackermann K, Stuart M, et al. Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain. J Virology. 2012;86:10112–22.
- Harcourt J, Tamin A, Xi L, et al. Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient. bioRxiv. 2020.
- Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020; Published online ahead of print. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32282022.
- Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405-7.
- Rouse, B., Sehrawat, S. Immunity and immunopathology to viruses: what decides the outcome?. Nat Rev Immunol. 2010; 10: 514–26.
- Kuldeep D, Sharun K, Ruchi T, et al. Coronavirus Disease 2019–COVID-19. Clinical Microbiol Rev. 2020; 33: e00028-20.
- Ulrich H, Pillat MM. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. Stem. Cell Rev Rep. 2020;16:434-40.
- Song P, Li W, Xie J, et al. Cytokine storm induced by SARS-CoV-2. ClinChimActa. 2020;509:280-87.
- Ana S, Darja D, Branka W, et al. Roles of Immune Mechanisms and Viral Load in the Pathogenesis of Crimean-Congo Hemorrhagic Fever.Clin VaccineImmunol.2010; 17: 1086-93.
- Walsh KA, Jordan K, Clyne B, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020;81:357-371.
- Liu WD, Chang SY, Wang J.et al. Prolonged virus shedding even after seroconversion in a patientwithCOVID-19. J .
- Infect. 2020 15.YongHuJiazhongSunZheDaiHaohuaDengXinLiQiHuangYuwenWuLiSunYanchengXu. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virology.2020; 127: 104371.
- Abdulamir AS, Hafidh RR. The Possible Immunological Pathways for the Variable Immunopathogenesis of COVID—19 Infections among Healthy Adults, Elderly and Children. Electron J Gen Med. 2020;17:em202.
- Shahamah M,BasheeruddinAM,Al-Yamani J. Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. J InfPublic Health. 2020;13: 1187-95.
- Rasheed AM, Fatak DF, Hashim HA, et al.The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq.Infez Med. 2020; 28:357-66.
- Perelson AS, Rong L, Hayden FG. Combination antiviral therapy for influenza: predictions from modeling of human infections. J Infect Dis. 2012; 205:1642-45.
- Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19:102567.
- McCreary EK, Angus DC. Efficacy of Remdesivir in COVID-19. JAMA. 2020;324:1041–42.
- van Kampen JJA, van de Vijver D, Fraaij PLA, et al.Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. medRxiv. 2020:2020.06.08.
- Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020;11:1446.
- Chowdhury MA, Hossain N, Kashem MA, et al. Immune response in COVID-19: A review. J Infect Public Health. 2020; 42: S1876-0341.
- Liu WJ, Zhao M, Liu K, et al T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res. 2017;137:82-92.
- Le Bert N, Tan AT, Kunasegaran K, et al SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature.2020; 584:457-62.
- Cañete PF, Vinuesa CG. COVID-19 Makes B Cells Forget, but T Cells Remember Cell. 2020;183:13-15.
- Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions. bioRxiv. 2020;2020.05.20.106401.
- Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. Available from: https://www.ncbi.nlm.nih.gov/books/NBK10757/
- Yang AP, Liu JP, Tao WQ, et al.The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. IntImmunopharmacol. 2020;84:106504.
- Zhang H, Wu T. CD4+T, CD8+T counts and severe COVID-19: A meta-analysis. J Infect. 2020;81:e82-e84.
- Chen, Z., John Wherry, E. T cell responses in patients with COVID-19. Nat Rev Immunol.2020; 20: 529–36.
- Ovsyannikova IG, Haralambieva IH, Crooke SN, et al. The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. Immunol Rev. 2020;296:205-19.
- Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020;370:89-94.
- Doshi P. Covid-19: Do many people have pre-existing immunity? BMJ 2020; 370: :m3563.
- Edridge AWD, Kaczorowska J, Hoste ACR, et al.Seasonal coronavirus protective immunity is short-lasting.. Nat Med. 2020; 10:1201-5.
- Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al.Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19.N Engl J Med. 2020; 383:1085-87.
|